Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer

doi:10.3969/j.issn.1673-8640.2022.04.007

Abstract

Abstract:

Objective To investigate the roles of serum human epidermal growth factor receptor-2（HER-2）and cluster of differentiation 44（CD44） in patients with colorectal cancer. Methods The levels of serum HER-2 and CD44 were determined by enzyme-linked immunosorbent assay in 38 colorectal cancer patients before and 2-3 d after operation,35 patients with benign colorectal diseases（benign disease group） and 36 healthy subjects（healthy control group）. The general data of all the subjects were collected. The correlation between serum HER-2 and CD44 levels in colorectal cancer patients was analyzed by Pearson correlation analysis. The efficiencies of each marker and combined determination in the auxiliary diagnosis of colorectal cancer were evaluated by receiver operating characteristic（ROC） curve. Results The preoperative serum HER-2 levels in colorectal cancer group were higher than those in benign colorectal disease and healthy control groups（P<0.05,P<0.000 1）. The preoperative serum CD44 levels in colorectal cancer group were higher than those in healthy control group（P<0.05）. Serum CD44 levels between colorectal cancer and benign colorectal disease group had no statistical significance（P>0.05）. The levels of serum HER-2 in colorectal cancer group were closely related to Ras mutation and peripheral nerve invasion（P<0.05）,and they were not related to serum CD44 levels（P>0.05）. Serum HER-2 and CD44 levels were not related to age,sex,tumor type,tumor size,TNM stage,lymph node metastasis and vascular invasion（P>0.05）. According to the results of ROC curve analysis,the areas under curves（AUC） of HER-2,CD44,carcinoembryonic antigen（CEA）,carbohydrate antigen 19-9（CA19-9） determinations and the combined determination in colorectal cancer diagnosis were 0.779,0.692,0.620,0.634 and 0.837,respectively. Postoperative levels of serum CD44 were reduced compared to preoperative levels in colorectal cancer group（P<0.000 1）,whereas no statistical significance was observed in serum HER-2 levels before and after operation（P>0.05）. Conclusions Serum HER-2 and CD44 levels are correlated in colorectal cancer patients. The combined determination of them may play a role in colorectal cancer auxiliary diagnosis and therapeutic monitoring.

Key words: Human epidermal growth factor receptor-2, Cluster of differentiation 44, Colorectal cancer

CLC Number:

R446.62

CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer[J]. Laboratory Medicine, 2022, 37(4): 336-341.

Figures/Tables 7

References 12

[1]	BILLER L H, SCHRAG D. Diagnosis and treatment of metastatic colorectal cancer:a review[J]. JAMA, 2021, 325(7):669-685. DOI URL
[2]	FALCO V D, NAPOLITANO, S ROSELLÓ, et al. How we treat metastatic colorectal cancer[J]. ESMO Open, 2020, 4(Suppl 2):e000813.
[3]	祁金英, 张玥, 陈亚静. 行无痛胃肠镜检查的老年患者实施健康安全管理的效果分析[J]. 中华老年医学杂志, 2021, 40(3):311-314.
[4]	WEIGAND S, HERTING F, MAISEL D, et al. Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist[J]. Cancer Res, 2012, 72(17):4329-4339. DOI URL
[5]	BAO W, FU H J, XIE Q S, et al. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells[J]. Gastroenterology, 2011, 141(6):2076-2087.e6. DOI URL
[6]	MERIC-BERNSTAM F, HURWITZ H, RAGHAV K P S, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer(MyPathway):an updated report from a multicentre,open-label,phase 2a,multiple basket study[J]. Lancet Oncol, 2019, 20(4):518-530. DOI URL
[7]	SARTORE-BIANCHI A, LONARDI S, MARTINO C, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer:the phase Ⅱ HERACLES-B trial[J]. ESMO Open, 2020, 5(5):e000911.
[8]	GUO Y J, LIU G, WANG X, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer[J]. Cancer Res, 1994, 54(2):422-426.
[9]	TSIGRIS C, KARAYIANNAKIS A J, ZBAR A, et al. Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer[J]. Cancer Lett, 2002, 184(2):215-222. DOI URL
[10]	UĞRAŞ N, YERCI Ö, ÖZGÜN G, et al. Immunohistochemical expression of CDX2,CK7,HER2 and HER4 in periampullary adenocarcinoma:implications for clinicopathology and patient outcomes[J]. Acta Gastroenterol Belg, 2017, 80(1):31-37.
[11]	SHI H, SHAO Y, LU W, et al. An analysis of HER2 amplification in cervical adenocarcinoma:correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification[J]. J Pathol Clin Res, 2021, 7(1):86-95. DOI URL
[12]	韩冬, 魏颖, 王曦迪, 等. 周围神经侵犯与结直肠癌临床病理因素及预后的关系[J]. 中华胃肠外科杂志, 2017, 20(1):62-66.

组别	例数	HER-2/（ng/mL）	CD44/（ng/mL）
结直肠癌组
术前	38	3.48±1.28^**#	1.84±1.00^*
术后	30	3.29±0.86	1.18±0.53^△
良性病变组	35	2.72±1.32^**	1.48±0.56
正常对照组	36	1.42±0.73	1.42±0.42

组别	例数	HER-2/（ng/mL）	CD44/（ng/mL）
结直肠癌组
术前	38	3.48±1.28^**#	1.84±1.00^*
术后	30	3.29±0.86	1.18±0.53^△
良性病变组	35	2.72±1.32^**	1.48±0.56
正常对照组	36	1.42±0.73	1.42±0.42

临床病理特征	例数	HER-2/（ng/mL）	CD44/（ng/mL）
年龄
<61岁	17	3.20±1.76	1.95±1.21
≥61岁	21	2.66±1.32	1.69±0.81
性别
男	24	3.10±1.87	1.98±1.21
女	14	2.57±0.59	1.50±0.34
肿瘤类型
结肠	18	2.77±1.28	1.63±0.84
直肠	20	3.07±1.79	1.96±1.16
肿瘤大小
<4 cm	15	3.23±1.63	2.03±1.38
≥4 cm	18	3.08±1.37	1.67±0.72
TNM分期
Ⅰ期	10	2.56±1.79	2.35±1.60
Ⅱ期	9	4.02±1.56	2.02±0.83
Ⅲ期	12	2.67±1.22	1.32±0.32
Ⅳ期	6	2.33±1.20	1.53±0.42
淋巴结转移
无	23	3.10±1.80	2.05±1.20
有	11	2.57±0.92	1.36±0.33
神经侵犯
无	12	2.14±1.17	1.80±1.01
有	22	3.17±1.44^*	1.67±0.64
脉管侵犯
无	19	2.74±1.41	1.72±0.84
有	15	2.89±1.49	1.71±0.73
Ras基因型
野生型	15	2.78±0.99	1.47±0.42
突变型	10	4.31±1.62^#	2.26±1.49

临床病理特征	例数	HER-2/（ng/mL）	CD44/（ng/mL）
年龄
<61岁	17	3.20±1.76	1.95±1.21
≥61岁	21	2.66±1.32	1.69±0.81
性别
男	24	3.10±1.87	1.98±1.21
女	14	2.57±0.59	1.50±0.34
肿瘤类型
结肠	18	2.77±1.28	1.63±0.84
直肠	20	3.07±1.79	1.96±1.16
肿瘤大小
<4 cm	15	3.23±1.63	2.03±1.38
≥4 cm	18	3.08±1.37	1.67±0.72
TNM分期
Ⅰ期	10	2.56±1.79	2.35±1.60
Ⅱ期	9	4.02±1.56	2.02±0.83
Ⅲ期	12	2.67±1.22	1.32±0.32
Ⅳ期	6	2.33±1.20	1.53±0.42
淋巴结转移
无	23	3.10±1.80	2.05±1.20
有	11	2.57±0.92	1.36±0.33
神经侵犯
无	12	2.14±1.17	1.80±1.01
有	22	3.17±1.44^*	1.67±0.64
脉管侵犯
无	19	2.74±1.41	1.72±0.84
有	15	2.89±1.49	1.71±0.73
Ras基因型
野生型	15	2.78±0.99	1.47±0.42
突变型	10	4.31±1.62^#	2.26±1.49

项目	AUC（95%CI^①）	最佳临界值	敏感性/%	特异性/%	阴性预测值/%	阳性预测值/%	Youden指数
HER-2	0.779（0.671~0.887）	1.53 ng/mL	84.2	66.7	80.0	72.7	0.509
CD44	0.692（0.573~0.811）	1.68 ng/mL	55.3	77.8	62.2	72.4	0.331
CEA	0.620（0.491~0.748）	2.66 ng/mL	63.2	61.1	61.1	63.2	0.243
CA19-9	0.634（0.496~0.771）	16.30 U/mL	44.7	100.0	63.2	100.0	0.447
联合检测	0.837（0.747~0.927）	0.45	76.3	80.6	76.3	80.6	0.569